Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by University of California, San Francisco
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Plexxikon
Information provided by (Responsible Party):
Hope Rugo, MD, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01596751
First received: May 7, 2012
Last updated: November 25, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)